Baudouin S V, Aitman T J, Johnson A J
Chest Clinic, Kent and Canterbury Hospital.
Thorax. 1988 May;43(5):385-7. doi: 10.1136/thx.43.5.385.
The role of prazosin, an alpha 1 adrenoceptor blocker, was investigated in patients with chronic stable asthma who continued to have symptoms despite conventional treatment. Forty patients were entered into a double blind, placebo controlled, crossover trial to examine the effect of adding oral prazosin (2 mg twice daily) to previous medication for three weeks. Sixteen patients withdrew from the study. The remaining 24 patients showed no significant change in peak expiratory flow, FEV1, forced vital capacity (FVC), FEV1/FVC ratio, diary card symptom scores, or dose of beta sympathomimetic.
对慢性稳定型哮喘患者（尽管接受了常规治疗仍有症状）使用α1肾上腺素能受体阻滞剂哌唑嗪的作用进行了研究。40名患者进入一项双盲、安慰剂对照的交叉试验，以检验在之前用药基础上加用口服哌唑嗪（每日两次，每次2毫克）持续三周的效果。16名患者退出了研究。其余24名患者的呼气峰值流速、第一秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC比值、日记卡症状评分或β拟交感神经药剂量均无显著变化。
